AKT1 and activated PI3K-delta syndrome: Targeted therapies for APDS focus on inhibiting the PI3K-AKT-mTOR pathway, with mTOR inhibitors (e.g., rapamycin/sirolimus) and selective PI3Kδ inhibitors (e.g., idelalisib or duvelisib) being the primary options, Recent studies have highlighted the potential curative role of allo-HSCT in APDS.